Meeting
2018 Genitourinary Cancers Symposium
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion.
Authors
Xiao Hu
Lycera Corp., Ann Arbor, MI
Xiao Hu , Xikui Liu , Hongxiu Li , Elizabeth Zawidzka , Garry Alan Weems , Yilin Gao , Brian Fox , H. Jeffrey Wilkins , Laura Carter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 424)
DOI
10.1200/JCO.2018.36.6_suppl.424
Abstract #
424
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation.
First Author: Laura Carter
Poster
2018 Gastrointestinal Cancers Symposium
Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion.
First Author: Garry Alan Weems
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Interleukin 17 in the tumor microenvironment: A potent target for anticancer immunotherapy?
First Author: Joseph Fabre
Poster
2023 ASCO Annual Meeting
Effect of MYC-targeting programmable epigenetic mRNA therapeutics on TME and immunotherapy responses.
First Author: Yan Moore